Supernus Pharmaceuticals (NASDAQ:SUPN) Rating Increased to Strong-Buy at Zacks Research

Key Points

• Zacks Research upgraded Supernus Pharmaceuticals from “hold” to “strong buy,” while the broader analyst consensus remains “Moderate Buy” with a target price of $62.83.
• Supernus shares opened at $47.64, compared with a 52-week range of $40.26 to $59.68; the company has a market capitalization of approximately $2.77 billion.
• Several institutional investors increased their positions in SUPN during the first quarter, including Millennium Management, which raised its stake by 370.5%.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) was upgraded by Zacks Research from a "hold" rating to a "strong-buy" rating in a report issued on Thursday,Zacks.com reports.

A number of other equities research analysts have also weighed in on SUPN. Cantor Fitzgerald lifted their target price on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an "overweight" rating in a research report on Thursday, July 9th. Wall Street Zen downgraded Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday. Finally, Weiss Ratings restated a "sell (d+)" rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $62.83.

Supernus Pharmaceuticals Stock Performance

Supernus Pharmaceuticals stock opened at $47.64 on Thursday. The company has a 50 day moving average price of $46.17 and a 200-day moving average price of $48.93. Supernus Pharmaceuticals has a fifty-two week low of $40.26 and a fifty-two week high of $59.68. The company has a market capitalization of $2.77 billion, a PE ratio of -24.81, a P/E/G ratio of 0.76 and a beta of 0.56.

Institutional Trading of Supernus Pharmaceuticals

A number of hedge funds have recently bought and sold shares of SUPN. Royal Bank of Canada lifted its stake in shares of Supernus Pharmaceuticals by 68.1% during the 1st quarter. Royal Bank of Canada now owns 11,669 shares of the specialty pharmaceutical company's stock worth $382,000 after purchasing an additional 4,729 shares during the last quarter. AQR Capital Management LLC grew its stake in Supernus Pharmaceuticals by 35.2% in the first quarter. AQR Capital Management LLC now owns 85,224 shares of the specialty pharmaceutical company's stock valued at $2,791,000 after purchasing an additional 22,182 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Supernus Pharmaceuticals by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,860 shares of the specialty pharmaceutical company's stock worth $978,000 after purchasing an additional 1,297 shares in the last quarter. Millennium Management LLC raised its holdings in Supernus Pharmaceuticals by 370.5% in the first quarter. Millennium Management LLC now owns 143,356 shares of the specialty pharmaceutical company's stock worth $4,695,000 after purchasing an additional 112,886 shares in the last quarter. Finally, Empowered Funds LLC lifted its position in shares of Supernus Pharmaceuticals by 16.0% during the first quarter. Empowered Funds LLC now owns 48,045 shares of the specialty pharmaceutical company's stock valued at $1,573,000 after buying an additional 6,619 shares during the last quarter.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company's marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source